Dr. Cohen on mTOR Inhibition in Head and Neck Cancer

Video

Dr. Ezra Cohen, from University of Chicago, on mTOR Inhibition in Head and Neck Cancer

Ezra Cohen, MD, Associate Professor of Medicine, University of Chicago, discusses the utility of inhibiting the mammalian target of rapamycin (mTOR) in head and neck cancer.

Cohen describes mTOR inhibition as being one of the more compelling targets in head and neck cancer. Drugs that inhibit mTOR, such as apamycin (sirolimus) and everolimus (Afinitor), are already approved for other indications and are currently being tested in head and neck cancer.

It remains difficult to determine how effective these therapies are as single agents, when given alone mTOR inhibition is most effective in the adjuvant setting and may help prevent recurrence. Adjuvant mTOR inhibition demonstrated efficacy in patients with minimal disease or no evidence of disease. Large or metastatic tumors, however, generally have multiple drivers and mTOR inhibition may not be as effective as a single agent.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,